Study of ACE1831 for active IgG4-related disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new drug called ACE1831 for people with active IgG4-related disease that affects more than one organ. It aims to see if the drug can safely control the disease and reduce the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are currently having a flare (active symptoms) of IgG4-related disease that needs treatment.
- In the past, IgG4 has affected at least two different organs or body sites, and at least one of those is actively flaring now (lymph nodes don't count).
- A recent blood test shows your IgG4 level is higher than normal.
- You are willing to take steroids for the flare and stop them completely before the study drug is given, and you need to use birth control if that applies to you.
- You have not had certain infections (like hepatitis, HIV, or tuberculosis) or a recent cancer, and you haven't used certain immune-suppressing drugs recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
This trial tests a new medicine called IMM0306 for IgG4-related disease, a condition where the immune system attacks multiple organs in your body. The study aims to see if IMM0306 can help control your disease and reduce flare-ups while using less steroid medication.
This study tests a drug called lenalidomide to see if it can help control active IgG4-related disease, a condition that causes inflammation and swelling in organs. The drug is taken by mouth, and the study compares it to a placebo (a pill with no medicine).
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This trial tests a new treatment using immune cells (CAR-NK) designed to target and kill specific cells that may cause IgG4-related disease (IgG4-RD). It is for people whose IgG4-RD has come back or not responded to standard treatments.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.